Flare Therapeutics Inc. has announced a US$123 million series B financing to support its work targeting novel transcription factors for cancer and other diseases.
Teitur Trophics ApS, a spinout from Aarhus University seeded by the Bioinnovation Institute in 2020, has completed a €28 million (US$30.1 million) series A financing. Teitur has developed a platform of first-in-class cyclic peptides with a novel mechanism that preserves neuronal function, and these peptides have the potential to treat a broad range of neurodegenerative diseases.
Thymmune Therapeutics Inc. has secured US$7 million in seed financing to support its work in developing scalable thymic cell therapies to restore immune function in aging and disease.
Cerevance Inc. has expanded its series B financing with an additional close of US$51 million, bringing the total series B financing to US$116 million. The proceeds will be used to advance Cerevance's therapeutics for central nervous system (CNS) diseases developed using its proprietary Nuclear Enriched Transcript Sort sequencing (Netsseq) platform.
Recurv Pharma Inc. is set to receive investment of up to $24 million from TVM Capital Life Science GmbH to support development up to phase IIa proof of concept of RP-001 to treat solid tumors.
HBM Alpha Therapeutics Inc. has completed seed financing to advance its lead programs, novel antibody therapies to treat congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS).
Bonum Therapeutics Inc., a spinout of Good Therapeutics Inc., which Roche Holding AG acquired in August, has announced a US$93 million series A financing. Bonum is developing new therapies based on the proprietary platform of allosterically regulated, conditionally active therapeutics developed by Good Therapeutics. The core platform makes possible the engineering and development of a wide range of medicines.
Novadip Biosciences SA has raised an additional €40 million in a series B equity round and nondilutive funding to accelerate the clinical development of two of the company's investigational adipose stem cell (ASC)-derived tissue regeneration products.